Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05078138 · ClinicalTrials.gov registry record · Phase 4

Impact of Erythropoietin on Hematological Adaptations and Physical Performance

A Phase 4 study of Physical Performance and Exercise-Induced Anemia, sponsored by United States Army Research Institute of Environmental Medicine.

Completed
Registry status
Phase 4
Development phase
8
Enrollment target
1
Study location

NCT05078138 is a Phase 4 study of Physical Performance and Exercise-Induced Anemia that has completed, run by United States Army Research Institute of Environmental Medicine. The registered enrollment target is 8 participants, below the 3,608-participant average among 6 other Physical Performance trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05078138, a Phase 4 study of Physical Performance and Exercise-Induced Anemia, has completed, sponsored by United States Army Research Institute of Environmental Medicine.

COMPLETED
Registry status
Phase 4
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

Negative hematological adaptations due to prolonged periods of strenuous physical activity may, in part, contribute to declines in physical performance during military operations. Exogenous erythropoietin (EPO) is a potential intervention that may be used to maintain hemoglobin (hgb), hematocrit (Hct), and physical performance during periods of high physical activity. The objective of the current study is to determine the ability of EPO to maintain hgb, Hct, and physical performance compared to baseline measures. Additionally, EPO may result in non-hematological adaptations which increase mitochondria biogenesis and alter substrate oxidation. As such, this study will also assess the influence of EPO on whole-body and skeletal muscle substrate oxidation. Eight healthy physically active individuals will be recruited to participate in this longitudinal trial. After exercise practice sessions, volunteers will complete baseline physical performance (time trial) and substrate oxidation testing. Participants will then receive EPO injections 3 times per week for 4 weeks. Diet and exercise will be controlled during the injection period. Participants will undergo four weeks of an intense physical training exercise program. Every seventh day during the injection period a safety blood sample, assessing hematocrit, will be drawn, and participants will complete a 5 km time trial to determine the time course of changes in physical performance can be detected. After the 4 weeks of EPO injections volunteers will complete the same physical performance and substrate oxidation testing. Substrate oxidation will be assessed during 90-min steady-state load carriage (30% body mass) exercise on a treadmill at 55 ± 5% of VO2peak. 6-6-\[2H2\] glucose tracer technique and indirect calorimetry will be used measure substrate oxidation. Muscle biopsies will be performed to measure muscle glycogen, enzyme activity, and molecular markers of metabolism and inflammation before, and immediately and 3-

Interventions

  • DRUG Epoetin Alfa

Study Locations (1)

Massachusetts

  • US Army Research Institute of Environmental Medicine - Natick

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2021-09-01
Est. Completion 2023-04-01
Phase Phase 4

What the Registry Record Tells You About NCT05078138

The ClinicalTrials.gov registry entry for NCT05078138 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,608-participant average among 6 other Physical Performance trials with a reported enrollment target (100% lower). The listed sponsor is United States Army Research Institute of Environmental Medicine, which has 59 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Physical Performance appearing as the primary indexed condition, and to 1 intervention - of which Epoetin Alfa is the first listed.

NCT05078138 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05078138 about?

NCT05078138 is a clinical study titled "Impact of Erythropoietin on Hematological Adaptations and Physical Performance". Negative hematological adaptations due to prolonged periods of strenuous physical activity may, in part, contribute to declines in physical performance during military operations. Exogenous erythropoietin (EPO) is a potential intervention that may be used to maintain hemoglobin (hgb), hematocrit (Hc...

What is the current status of trial NCT05078138?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2021-09-01. Estimated completion is 2023-04-01.

What conditions does trial NCT05078138 study?

This clinical trial studies the following conditions: Physical Performance, Exercise-Induced Anemia.

What interventions are being tested in trial NCT05078138?

The interventions under investigation include: Epoetin Alfa (DRUG).

Who is sponsoring clinical trial NCT05078138?

This trial is sponsored by United States Army Research Institute of Environmental Medicine, which has 59 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05078138 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Physical Performance

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.